Why MBAs Are All Going East
Why Bing's In Love With Farmville
Telling Friends Where You Are
Emerging markets are forecast to contribute around 70% of pharma growth in the next five years
Pfizer’s acquisition of Ratiopharm will make it influential in generics
Fortis has agreed to buy the stake from buyout firm TPG Capital
Emerging markets are forecast to contribute around 70% of pharma growth
Ranbaxy has failed to secure FDA approval to launch a generic version of a blockbuster urinary drug Flomax
Last year, the Forbes list included telecom czar Sunil Mittal, NRI businessman Anil Agarwal and HCL Tech Chairman Shiv Nadar
The facility makes Penems and Penicillins and is forecast to deliver $40 mn on an annualised basis
New rules are unlikely to stop doctors from promoting drug brands
Will Indian doctors warm to GE’s new pocket-size ultrasound machine?
Ranbaxy had incurred losses in three consecutive quarters to March
Indian firms have a good success rate in fighting patent holders in the US
While the government is expected to approve the Medical Council of India’s (MCI) proposal to introduce a four-year Bachelor of Rural Medicine and Surgery (BRMS) course
IDMA is pressing for the excise duty on drugs to be held at 4 per cent
Pfizer is investing in a new R&D facility in India after a long gap
Pfizer is considering teaming up with one or more Japanese generic drug makers
In spite of 16 years of arduous research, no new drug has made it out of Indian labs. Here’s why
